Protease inhibitors for the treatment of human immunodeficiency virus infection

American Journal of Health-System Pharmacy

Volumn 55, Issue 3, 1998, Pages 233-254

  Kakuda, Thomas N ^a,b   Struble, Kimberly A ^c   Piscitelli, Stephen C ^d,e  

^a University of Minnesota   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d NIH

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Antivirals; Compliance; Costs; Dosage; Drug administration; Drug interactions; Food; HIV infections; Human immunodeficiency virus; Indinavir sulfate; Mechanism of action; Nelfinavir mesylate; Patient information; Pharmacists; Pharmacokinetics; Resistance; ; Ritonavir; Saquinavir messyalte; Toxicity

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NELFINAVIR; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; CROSS RESISTANCE; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG INFORMATION; DRUG SCREENING; DRUG SENSITIVITY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEPHROLITHIASIS; PARESTHESIA; PATIENT COMPLIANCE; PATIENT INFORMATION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0032007325     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.3.233     Document Type: Review

References (127)

1. Kramer RA, Schaber MD, Skalka AM et al. HTLV-III gag protein is processed in yeast cells by the virus pol-protease. Science. 1986; 231:1580-4.
2. Kohl NE, Emini EA, Schlief WA et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A. 1988; 85:4686-90.
3. Gottinger HG, Sodroski JG, Haseltine WA. Role of capsid precursor processing and myrisoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1989; 86:5781-5.
4. Pettit SC, Michael SF, Swanstrom R. The specificity of the HIV-1 protease. Perspect Drug Discov Res. 1993; 1:69-83.
5. Roche Invirase clears FDA in 97 days as first approved protease inhibitor; new formulation in study; international confirmatory trial; power increased. FDC Rep. 1995; 57 (Dec 11):3-4.
6. Abbott Norvir for HIV reduces death risk 40%, reduces disease progression risk 56% in advanced HIV; FDA approves ritonavir March 1 in record 72 days. FDC Rep. 1996; 58 (Mar 4):7-8.
7. Merck Crixivan temporary distribution to begin filling scripts March 25 through independent pharmacy service; scale-up facilities to be ready in six months. FDC Rep, 1996; 58 (Mar 18):3-4.
8. Agouron Viracept to be compared to Norvir in clinical end-point study. FDC Rep. 1997; 59 (Mar 17):T&G 1.
9. Navia MA, Fitzgerald PMD, McKeever BM et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature. 1989; 159:87-94.
10. Pillay D, Bryant M, Getman D et al. HIV-1 protease inhibitors: their development, mechanism of action and clinical potential. Rev Med Virol. 1995; 5:23-33.
11. Miller M, Sathyanarayana BK, Toth MV et al. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 Å resolution. Science. 1989; 246:1149-52.
12. Roberts NA, Martin JA, Kinchington D et al. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990; 248:358-61.
13. Erickson JR, Neidhart DJ, van Drie J et al. Design, activity, and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science. 1990; 249:527-33.
14. Lam PY, Jadhav PK, Eyermann CJ et al. Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science. 1994; 263:380-4.
15. Navia MA, Sato VL, Tung RD. Design of VX-478, a potent inhibitor of HIV protease. Int Antivir News. 1995; 9:143-5.
16. Saquinavir. Drugs Future. 1995; 20:321-5.
17. Graul A, Castañer J. Ritonavir. Drugs Future. 1996; 21:700-5.
18. Mealy N, Castañer J. Indinavir. Drugs Future, 1996; 21:600-9.
19. Ireland CD, Castañer J. KNI-272. Drugs Future. 1996; 21:1022-7.
20. Loeb DD, Hutchison CA III, Edgell MH et al. Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases. J Virol. 1989; 63:111-21.
21. Leonard JM. Perspectives in HIV protease inhibitors. Adv Exp Med Biol. 1996; 394:319-25.
22. Barry M, Gibbons S, Back D et al. Protease inhibitors in patients with HIV disease. Clin Pharmacokinet. 1997; 32:194-209.
23. McDonald CK, Kuritzkes DR. Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med. 1997; 157:951-9.
24. 4 lymphocytes in HIV-1 infection. Nature. 1995; 373:123-6.
25. Wei X, Ghosh SK, Taylor ME et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature. 1995; 373:117-22.
26. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science. 1995; 267:483-9.
27. Connor RI, Ho DD. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol. 1994; 68:4400-8.
28. Mohri H, Singh MK, Ching WTW et al. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc Natl Acad Sci U S A. 1993; 30:25-9.
29. Nájera I, Richman DD, Olivares I et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses. 1994; 10:1479-88.
30. Nájera I, Holgu'n A, Quinones-Mateu E et al. Pol gene qua sispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol. 1995; 69:23-31.
31. Yamaguchi K, Byrn RA. Clinical Isolates of HIV-1 contain few pre-existing proteinase inhibitor resistance-conferring mutations. Biochim Biophys Acta. 1994; 1253:136-40.
32. Vanhove GF, Schapiro JM, Winters MA et al. Patient compliance and drug failure in protease inhibitor monotherapy. JAMA. 1996; 276:1955-6.
33. Jacobsen H, Hönggi M, Ott M et al. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J Infect Dis. 1996; 173:1379-87.
34. Jacobsen H, Yasargil K, Winslow DL et al. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase Inhibitor Ro 31-8959. Virology. 1995; 206:527-34.
35. Condra JH, Schleif WA, Blahy OM et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature. 1995; 374:569-71.
36. Molla A, Korneyeva M, Gao Q et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 1996; 2:760-6.
37. Markowitz M, Mo H, Kempf DJ et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol. 1995; 69:701-6.
38. Korneyeva M, Molla A, Kempf D et al. Clinical and virological responses to ritonavir, an inhibitor of HIV protease. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 10.
39. El-Farrash MA, Kuroda MJ, Kitazaki T et al. Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol. 1994; 68:233-9.
40. Ho DD, Toyoshima T, Mo H et al. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C-2 symmetric protease inhibitor. J Virol. 1994; 68:2016-20.
41. Patick AK, Duran M, Cao Y. Genotypic analysis of HIV-1 variants isolated from patients treated with the protease inhibitor nelfinavir, alone or in combination with d4T or AZT and 3TC. Paper presented at Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 23.
42. Patick AK, Mo H, Markowitz M et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother. 1996; 40:292-7.
43. Sampson M, Torres RA, Stein AJ et al. Ritonavir-saquinavir combination treatment in protease inhibitor experienced patients with advanced HIV disease. Paper presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 1997 Sep 29.
44. Markowitz M, Saag M, Powderly W et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995; 333:1534-9.
45. Stein DS, Fish DG, Bilello JA et al. A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).AIDS. 1996; 10:485-92.
46. Nelfinavir package insert. La Jolla, CA: Agouron Pharmaceuticals; 1997 Mar.
47. Saquinavir package Insert. Nutley, NJ: Roche Laboratories; 1996 Jun.
48. Indinavir package insert. West Point, PA: Merck & Co.; 1996 Mar.
49. Ritonavir package insert. North Chicago, IL: Abbott Laboratories; 1996 May.
50. Stahle L, Martin C, Svensson J-O et al. Indinavir in cerebrospinal fluid of HIV-1 infected patients. Lancet. 1997; 350:1823. Letter.
51. Delavirdine package insert. Kalamazoo, MI: Pharmacia & Upjohn; 1997 Apr.
52. Salgo M, Beattie D, Bragman K et al. Saquinavir vs Hivid vs combination as treatment for advanced HIV infection in patients discontinuing/unable to take Retrovir. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 8.
53. Collier AC, Coombs RW, Schoenfeld DA et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med. 1996; 334:1011-7.
54. Cameron DW, Heath-Chiozzi M, Kravcik S. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 7-12.
55. Abbott Norvir for HIV reduces death risk 40%; reduces disease progression risk 55% in advanced HIV. FDC Rep. 1996; 58 (Mar 4):7-8.
56. Mathez D, Bagnarelli P, De Truchis P et al. A triple combination of ritonavir+AZT+DDC as first line treatment of patients with AIDS: update. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 8.
57. 3. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 11.
58. Gulick RM, Mellors J, Havlir D et al. Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC). Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 10.
59. Powderly W, Sension M, Conant M et al. The efficacy of Viracept (nelfinavir mesylate, NFV) in pivotal Phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC. Paper presented at Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 22-27.
60. Henry K, Lamarca A, Myers R et al. The safety of Viracept (nelfinavir mesylate, NFV) in pivotal Phase II/III double-blind randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC. Paper presented at Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 23.
61. 4+ T-cell counts in HIV-infected patients. Ann Intern Med. 1996; 124:1039-50.
62. Schapiro JM, Winters MA, Vierra M et al. Causes of long term efficacy and/or drug failure in protease (PR) inhibitor monotherapy. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 8.
63. Kelleher AD, Carr A, Zaunders J et al. Alteration in the immune response of human immunodeficiency virus (HIV) infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis. 1996; 173:321-9.
64. Leavitt R, Massari F, Nessly M et al. Antiviral activity of indinavir plus zidovudine compared to indinavir or zidovudine alone in antiretroviral naive patients. Paper presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; 1996 Sep 16.
65. Pedneault L, Ellion R, Adler M et al. Stavudine (d4T), didanosine (ddI), and nelfinavir combination therapy in HIV-infected subjects: antiviral effect and safety in an ongoing pilot study. Paper presented at Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 23.
66. Glaxo/Vertex HIV protease inhibitor 141W94 shows 99% reduction in viral load. FDC Rep. 1996; 58 (Sep 23):9-10.
67. 3. Paper presented at Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 23.
68. Kempf DJ, Marsh KG, Kumar G et al. Pharmacokinetic en hancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 1997; 41:654-60.
69. Cohen C, Sun E, Cameron W et al. Ritonavir-saquinavir combination treatment in HIV-infected patients. Paper presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; 1996 Sep 16.
70. Kravcik S, Sahai J, Kerr B et al. Nelfinavir mesylate (NFV) increases saquinavir soft-gel capsule (SQV-SGC) exposure in HIV+ patients. Paper presented at Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 23.
71. Mueller BU, Zuckerman J, Nelson RP Jr et al. A Phase I/II study of the protease inhibitor ritonavir (ABT-538) in children with HIV infection. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 10.
72. Krogstad P, Kerr B, Anderson R et al. Phase I study of the HIV-protease inhibitor nelfinavir mesylate (NFV) in HIV+ children. Paper presented at Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 24.
73. Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR. 1996; 45:468-72.
74. Centers for Disease Control and Prevention. Case-control study of HIV seroconversion in health care workers after percutaneous exposure to HIV infected blood-France, United Kingdom, and United States, January 1988-August 1994. MMWR. 1995; 44:929-33.
75. Vella S. HIV therapy advances: update on a proteinase inhibitor. AIDS. 1994; 8(suppl 3):S25-9.
76. Danner SA, Carr A, Leonard JM et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med. 1995; 333:1528-33.
77. Duong M, Sgro C, Grappin M et al. Renal failure after treatment with ritonavir. Lancet. 1996; 348:693. Letter.
78. Daudon M, Estépa L, Viard JP et al. Urinary stones in HIV-1-positive patients treated with indinavir. Lancet, 1997; 349:1294-5.
79. Bräu N, Leaf HL, Wieczorek RL et al. Severe hepatitis in three AIDS patients treated with indinavir. Lancet. 1997; 349:924-5. Letter.
80. Stein DS, Fish DG, Bilello JA et al. A 24-week open label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS. 1996; 10:485-92.
81. Deutsch P, Teppler H, Squires K et al. Antiviral activity of L-735,524 and HIV protease inhibitor, in infected patients. Paper presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; 1996 Sep 16.
82. FDA protease inhibitor letter urges monitoring of hemophiliacs. FDC Rep. 1996; 57:T&G 3.
83. Ginsburg C, Salmon-Ceron D, Vassilief D et al. Unusual occurrence of spontaneous hematomas in three asymptomatic HIV-infected haemophilia patients a few days after the onset of ritonavir treatment. AIDS. 1997; 11:388-9.
84. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet. 1997; 350:1596. Letter.
85. Herry I, Bernard L, de Truchis P et al. Hypertrophy of the breasts in a patient treated with indinavir. Clin Infect Dis. 1997; 25:937-8.
86. Kumar GN, Rodrigues AD, Buko AM et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996; 277:423-31.
87. Kerr B, Lee C, Yuen G et al. Overview of in vitro and in vivo, drug interaction studies of nelfinavir, a new HIV-1 protease inhibitor. Paper presented at Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 23.
88. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease Inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos. 1997; 25:256-66.
89. Chiba M, Hensleigh M, Nishime JA et al. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos. 1996; 24:307-14.
90. Sun E, Heath-Chiozzi M, Cameron DW et al. Concurrent ritonavir and rifabutin increases the risk of rifabutin-associated adverse effects. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 8.
91. Hsu A, Granneman GR, Witt G et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 8.
92. Quellet D, Hsu A, Qian J et al. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 8.
93. Caballero-Granado FJ, Viciana P, Cordero E et al. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient. Antimicrob Agents Chemother, 1997; 41:1207. Letter.
94. Centers for Disease Control and Prevention. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR. 1996; 45:921-5.
95. Cohen MR. Name confusion with new protease inhibitors. Hosp Pharm. 1996; 31(8):930-4.
96. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA, 1993; 270:474-8.
97. Carpenter CJ, Fischl MA, Hammer SM et al. Antiretroviral therapy for HIV infection. JAMA. 1996; 276:146-54.
98. Doherty MC, ed. Red book. Montvale, NJ: Medical Economics; 1997.
99. Binkley D, Waller L, Potts L et al. Pharmacists as HIV/AIDS information resources: survey of Alabama pharmacists. AIDS Educ Prev. 1995; 7:455-66.
100. Foisy MM, Tseng A, Blaikie N. Pharmacist's provision of continuity of care to patients with human immunodeficiency virus infection. Am J Health-Syst Pharm. 1996; 53:1013-7.
101. Devine B, Chow VC. A continuity of care, pharmaceutical care model for HIV patients. Calif J Health-Syst Pharm. 1996; Jan/Feb:6-8.
102. 2-symmetric dimers as novel inhibitors of HIV-1 proteinase. J Med Chem. 1992; 35:3080-1.
103. Tummino PJ, Ferguson D, Hupe D. Competitive inhibition of HIV-1 protease by warfarin derivatives. Biochem Biophys Res Commun. 1994; 201:290-4.
104. Thairsrivongs S, Tomich PK, Watenpaugh KD et al. Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidie inhibitors. J Med Chem. 1994; 37:3200-4.
105. Poppe SM, Slade DE, Chong KT et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother. 1997; 41:1058-63.
106. Poppe SM, Slade D, Chong K et al. HIV-1 resistant to multiple peptidemimetic protease inhibitors lack significant cross-resistance to the dihydropyrone inhibitors. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 11.
107. Rosé JR, Craik CS. Structure-assisted design of nonpeptide human immunodeficiency virus-1 protease inhibitors. Am J Respir Crit Care Med. 1994; 150:5176-82.
108. Wang S, Milne GWA, Van X et al. Discovery of novel, nonpeptide HIV-1 protease inhibitors by pharmacophore searching. J Med Chem. 1996; 39:2047-54.
109. 1-acid glycoprotein. J Infect Dis. 1995; 171:546-51.
110. 1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J Infect Dis. 1997; 175:1063-70.
111. Leroux J-C, Cozens RM, Roesel JL et al. pH-sensitive nanoparticles: an effective means to improve the oral delivery of HIV-1 protease inhibitors in dogs. Pharm Res. 1996; 13:485-7.
112. Bender A, Immelmann A, Kreuter J et al. Nanoparticles as drug carrier for antiviral agents against HIV. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 8.
113. Falloon J, Owen C, Metcalf J et al. Indinavir and interleukin-2 in HIV: one year follow-up. Paper presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; 1996 Sep 15.
114. Sham H, Kempf D, Molla A et al. Design, synthesis and biological properties of ABT-378, a highly potent HIV protease inhibitor. Paper presented at Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC; 1997 Jan 24.
115. Alteri E, Bold G, Cozens R et al. CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrob Agents Chemother. 1993; 37:2087-92.
116. Mestan J, Bold G, Capraro HG et al. In vitro profile of CGP 61 783, an HIV-1 protease inhibitor of a new structural class. Paper presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; 1996 Sep 15.
117. Cozens RM. Biological characterization of a novel HIV-protease inhibitor, CGP 70726, a representative of a new structural class. Paper presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA; 1996 Sep 15.
118. Hodge CN, Aldrich PE, Bacheler LT et al. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and x-ray crystal structure of DMP 450. Chem Biol. 1996; 3:301-14.
119. Kim CU, McGee L, Krawczyk S et al. Discovery of potent, orally bioavailable, non-peptidic, cyclic sulfones as HIV protease inhibitors. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 8.
120. Humphrey RW, Nguyen B-Y, Wyvill KM et al. A Phase I trial of HIV protease inhibitor KNI-272 in patients with AIDS or symptomatic HIV infection. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 10.
121. Lee TG, Kwon YD, Choi HI et al. Analysis of HIV-1 variants resistant to irreversible protease inhibitors, LB71148 and LB71262. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 8.
122. Lehr P, Billich A, Charpiot B et al. Inhibitors of human immunodeficiency virus type 1 protease containing 2-aminobenzyl-substituted 4-amino-3-hydroxy-5-phenylpentanoic acid: synthesis, activity, and oral bioavailability. J Med Chem. 1996; 39:2060-7.
123. Lamarre D, Croteau G, Wardrop E et al. Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother. 1997; 41:965-71.
124. Thaisrivongs S, Aristoff PA, Tarpley WG et al. The dihydropyrones: third-generation, non-peptidic HIV protease inhibitor development candidates. Paper presented at 11th International Conference on AIDS. Vancouver, Canada; 1996 Jul 9.
125. Acosta EP, Henry K, Weller D et al. Indinavir pharmacokinetics and relationships between exposure and antiviral effects. Paper presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 1997 Sep 28.
126. Harris M, Durakovic C, Pae S et al. Virologic response to indinavir/nevirapine/3TC correlates with indinavir trough concentrations. Paper presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 1997 Sep 28.
127. Burger DM, Koopsman PP, Brinkman K et al. Therapeutic drug monitoring of the HIV protease inhibitor indinavir. Paper presented at 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada; 1997 Sep 28.